Foreign pharmaceutical companies face specific procedural hurdles when seeking interim relief in Russia. A step-by-step guide. Make an enquiry.
Unlike English procedural law, which offers a relatively consolidated route to interim injunctive relief via a single application supported by a cross-undertaking in damages, Russian civil procedure operates through a distinct framework for interim measures and asset preservation — one that carries sector-specific nuances of material consequence to foreign pharmaceutical companies. For in-house counsel managing Russian subsidiaries, distributors, or licence arrangements, the difference between a well-timed application and a procedural misstep can determine whether a dispute is recoverable at all. This guide sets out the key steps for obtaining and maintaining interim measures in Russian proceedings, with particular attention to the pharmaceutical sector.
Before any application is filed, in-house counsel should carry out a structured readiness assessment. The following items should be confirmed and documented:
Note: Under Russian civil procedure rules, a court considering an interim application may require the applicant to provide a counter-security (a guarantee against potential losses to the respondent if the claim ultimately fails). Pharmaceutical companies should assess this exposure in advance and establish whether a bank guarantee or cash deposit will be required.
If your company holds pharmaceutical assets or regulatory approvals in Russia and faces a counterparty dispute, an early review of your enforcement position is advisable before the limitation clock becomes live. Make an enquiry: info@vetrovpartners.com |
The threshold for granting interim measures in Russian proceedings is based on two cumulative tests that the court applies before considering the application on its merits. First, the applicant must demonstrate that, without the measure, enforcement of a future judgment or award will be substantially complicated or rendered impossible. Second, the measure requested must be proportionate in scope to the claim asserted.
For pharmaceutical companies, the first test is frequently met where the at-risk assets are liquid — cash balances or receivables from distributors — because these can be moved rapidly within or outside Russia. It is less straightforward where the assets in question are regulatory in nature: a marketing authorisation held by the Russian counterparty, for example, cannot be "frozen" in the conventional sense, and an applicant seeking to restrain a counterparty from transferring or surrendering such an authorisation will need to frame the application carefully.
The proportionality test requires that the value of assets to be preserved does not materially exceed the principal claim. In-house counsel should identify a defensible claim quantum before the application is filed, since courts will limit the scope of the preservation order to that figure. Where a pharmaceutical supply dispute involves multiple product lines with different pricing, a disaggregated claim schedule is more useful than a single aggregate number.
Russian courts have discretion at every stage of an interim application. The absence of an automatic mechanism comparable to a without-notice freezing order under English procedure means that the quality of the written application itself carries substantial weight.
The procedural vehicle for interim relief depends on the forum in which the underlying claim is, or will be, brought. This step is frequently underestimated by in-house counsel unfamiliar with Russian procedure, and getting it wrong can result in the application being refused on purely formal grounds.
For disputes litigated before the Russian state arbitrazh courts, interim measures are applied for directly in those courts. The application may be filed at any stage of proceedings, including before the main statement of claim is submitted, though the court will require a main claim to follow promptly. Applications made before the claim is filed carry a higher risk of refusal if the court is not satisfied that urgency is genuine.
For disputes referred to a Russian-seated domestic arbitration tribunal, the parties may apply to the arbitration tribunal itself for interim relief, or to the competent state arbitrazh court for support. The latter route is available under Russian arbitration legislation and is the more reliable option where speed is the priority, since state courts can act more quickly than most institutional rules permit.
For disputes before an international arbitral institution seated outside Russia, the enforcement of interim orders made by that institution inside Russia requires recognition by a Russian state court. This is a significant procedural step and should be anticipated at the outset of the arbitration rather than treated as a fallback. In-house counsel advising on pharmaceutical distribution disputes with Russian counterparties should raise this issue with arbitration counsel early. The firm's Cross-border Disputes & Arbitration practice can assist with Russian-side coordination in these scenarios.
The EAEU dimension is also relevant here. Pharmaceutical companies holding marketing authorisations registered under the EAEU unified registration procedure may have assets in multiple EAEU jurisdictions linked to a single Russian counterparty. Interim protection strategies should be assessed across the relevant jurisdictions, not in Russia alone.
A Russian interim measures application is a written submission to the court: there is no oral argument on the interim application in most proceedings before it is decided. The quality of the written document is therefore the primary variable the applicant controls.
The application must identify the specific measure requested (asset freeze, prohibition on certain actions, arrest of goods), the assets to which it applies (by account number, property address, or asset description), the legal basis under the applicable procedural rules, and the factual grounds for urgency. General or formulaic applications are routinely refused.
For pharmaceutical companies, the application frequently needs to address assets that are sector-specific. The following categories require particular attention: registered pharmaceutical products held in the counterparty's name with Roszdravnadzor (the Federal Service for Health Surveillance), stock held in licensed pharmaceutical warehouses, and exclusive distribution rights under agreements that have commercial value independent of the underlying inventory. Each of these requires a tailored description in the application.
Under Russian civil procedure rules, a court deciding an interim application must act within one day of receipt for applications filed in conjunction with or after the main claim. This is the window within which counsel must have the document in final form. Delays in instructing Russian counsel — even of 24 to 48 hours — can cost the applicant the element of surprise that makes the measure effective against liquid assets.
Foreign pharmaceutical companies with Russian assets should be aware that delays in this process are among the most consequential recoverable errors in Russian litigation. A counterparty that becomes aware of impending proceedings may move assets — including cash balances held in Russian clearing accounts — before a preservation order is served. The statutory timeline for a court to act creates an obligation on applicants to be ready before, not after, the moment they decide to file.
For in-house counsel assessing whether an interim application is viable in a live pharmaceutical dispute in Russia, an initial 30-minute meeting is available at no charge. Make an enquiry: info@vetrovpartners.com |
Once an interim order is granted, the applicant receives a writ of execution from the court, which must be served on the relevant institutions — typically the bank holding the counterparty's account, the Rosreestr registry (for real property), or the Federal Bailiff Service — in order for the order to have effect. The service step is not automatic; the applicant is responsible for transmitting the writ to the appropriate bodies promptly.
In the pharmaceutical sector, where counterparties may operate through multiple distribution entities, each with separate bank accounts across Russian regions, this service step requires coordination. A single order naming one account at one bank will not capture assets held elsewhere. The scope of the application should therefore identify all known accounts and asset locations, not merely the primary one.
Interim orders in Russian proceedings are time-limited where the court grants them in advance of the main claim being filed. The main claim must follow within fifteen days of the interim order being made; failure to file within that period gives the counterparty grounds to apply for the order to be lifted. This is a hard deadline that in-house counsel should communicate clearly to their internal dispute-resolution chain.
The counterparty is entitled to apply to the court for the order to be varied or discharged at any stage of proceedings, and may do so on substantive grounds (disputing the claim basis) or procedural grounds (challenging the scope of assets covered). Applicants should prepare for this challenge from the moment the order is served.
Further guidance on the strategic considerations that inform scope and duration of interim measures is available in the firm's article on strategic considerations in interim measures applications in Russia. For the regulatory context following recent legislative changes affecting the availability of these orders, see also the firm's note on legislative amendments affecting interim measures in Russia.
An interim preservation order is not a static outcome. It requires ongoing management: the applicant must ensure the main proceedings advance on schedule, respond to any challenge applications by the counterparty, and consider whether the scope of the order remains proportionate as the main proceedings evolve.
In pharmaceutical sector disputes, a further complexity arises where the preserved assets include perishable goods, products approaching regulatory expiry, or inventory subject to cold-chain requirements. Courts have considered applications to modify preservation orders to permit the sale or destruction of such goods, with the net proceeds held in escrow. In-house counsel should anticipate this issue — both as an applicant managing the order and as the operator responsible for the preserved goods — and address it in the original application if the inventory characteristics make it foreseeable.
Discharge of the order — whether by settlement, judgment, or applicant choice — also requires a procedural step. The writ of execution must be recalled from the executing institutions; failing to do so can create operational complications for the counterparty that generate subsidiary liability claims. Where a dispute resolves by settlement and the counterparty's goodwill in the ongoing relationship is commercially relevant, managing the discharge efficiently is part of the overall resolution strategy.
For foreign pharmaceutical companies managing the full lifecycle of a Russian dispute — from pre-claim assessment through interim measures to judgment enforcement — the Cross-border Disputes & Arbitration practice at Vetrov & Partners provides Russian-qualified counsel with direct partner involvement at every stage. Matters of this nature are also tracked at the firm's Matters page.
Q: How long does a Russian arbitrazh court typically take to decide an interim measures application in a commercial dispute?
A: Where the interim application is filed together with or after the main statement of claim, Russian procedural rules require the court to consider it within one day of receipt. In practice, courts in the principal commercial centres typically act within that window for straightforward applications, though more complex multi-asset applications or those involving sector-specific assets — such as pharmaceutical regulatory approvals — may take longer if the court requests supplementary documentation. Applicants should treat the one-day statutory period as the target, not the guarantee, and ensure their application is complete and unambiguous on first filing.
Q: What documents does a foreign pharmaceutical company need to support an interim measures application before a Russian state court?
A: The core documentation for a Russian interim application includes: the primary commercial agreement underlying the dispute (supply contract, licence agreement, or distribution agreement), evidence of the obligation breached or the claim basis (invoices, correspondence, notice of default), identification of the specific assets to be preserved (account details, property descriptions, registry references), and a statement of the claim quantum. Where the applicant is a foreign entity, notarised and apostilled corporate documents confirming authority to commence proceedings are also required. The application itself is drafted in Russian; foreign documents must be translated by a certified translator. The absence of any of these elements is a common basis for courts to decline to act within the one-day window.
Q: What happens if the counterparty has already transferred assets outside Russia before the interim order is served?
A: If assets have been transferred before the order is made, recovery depends on whether the transfer constitutes a transaction that can be challenged on substantive grounds — for example, as a transaction made at undervalue or with an intent to defeat creditors' claims, which Russian insolvency and civil legislation both address. If the counterparty is already insolvent or close to insolvency, the matter crosses into restructuring and insolvency territory, and a separate creditor strategy may be required. The firm's Restructuring & Insolvency practice advises foreign creditors in this scenario. Where assets have been moved to another EAEU jurisdiction, enforcement cooperation mechanisms between EAEU member states may be relevant, and cross-border coordination with counsel in the relevant jurisdiction is advisable.
This briefing is general information and does not constitute legal advice. For advice on a specific matter, write in confidence to info@vetrovpartners.com.
Our team advises foreign clients on exactly these questions across Russia and the EAEU region. Initial 30-minute consultation — complimentary.
Make an enquiry